Astellas appoints VP, global medicine safety
This article was originally published in Scrip
Executive Summary
Astellas Pharma Global Development – a subsidiary of Astellas Pharma Inc, based in Tokyo, Japan – has appointed Robin J McGarry vice-president, global medicine safety head. For the past 13 years Ms McGarry worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services. And in the past she was vice-president of worldwide safety at Pfizer. Furthermore, Astellas Pharma Global Development has promoted Mark Weinberg to vice-president of Global Clinical Science at the company. Mr Weinberg joined Astellas in 2011 as global therapeutic area head in CNS and pain.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.